Sionna Therapeutics Investors Face 90% Loss After Failed Drug Trial

The legal firm SueWallSt, a division of Levi & Korsinsky LLP, has launched an inquiry into whether the company misled shareholders regarding its drug development progress prior to the corrective disclosure. Shares had traded above $44 in July 2026 before the trial results were published, revealing a placebo-adjusted sweat chloride change of only -1.0 mmol/L. Sionna Therapeutics confirmed it will not advance the candidate, leaving early investors with significant financial exposure.

Legal representatives state that participation in the investigation does not require current ownership of the stock. Eligibility is determined by purchase timing and documented losses rather than a minimum threshold or holding status. Investors seeking a case evaluation are being asked to provide brokerage records detailing share quantities and purchase dates. The firm emphasizes that claimants generally do not need to appear in court or provide testimony, as the inquiry focuses on potential securities law violations related to the period preceding the stock price decline.